Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. (NCT06482905)
A Phase I, Open-Label, Single/Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Antitumor Activity of TX103 CAR-T Cell Injection (TX103) in Subjects With Recurrent or Progressive Grade 4 Glioma.
🩺 Plain-English Summary (8th-Grade Level)
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic in Arizona — Phoenix, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Mayo Clinic in Arizona — Phoenix, Arizona
- Mayo Clinic in Florida — Jacksonville, Florida
- Mayo Clinic in Rochester — Rochester, Minnesota
- Beijing Tiantan Hospital — Beijing, Beijing Municipality
📞 Contact the Study Coordinator
Phone: +(86)13509312934
Email: fengrui@tcelltech.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in High-grade Glioma
- Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma — Santa Monica, California
- A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors — Basking Ridge, New Jersey
- Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG — Palo Alto, California
- Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac — New York, New York
- IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG) — Gainesville, Florida
- Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas — New York, New York
Explore by condition: All High-grade Glioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.